Hollencrest Capital Management Cyto Dyn Inc. Transaction History

Hollencrest Capital Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$0.39 - $1.23 $96,330 - $303,810	247,000 New	247,000 $103,000
Q1 2022 Apr 18, 2022	SELL	$0.37 - $1.02 $4,625 - $12,750	-12,500 Closed	0 $0
Q4 2021 Jan 07, 2022	SELL	$0.98 - $1.86 $4,410 - $8,370	-4,500 Reduced 26.47%	12,500 $12,000
Q3 2021 Oct 13, 2021	SELL	$1.27 - $2.46 $27,305 - $52,890	-21,500 Reduced 55.84%	17,000 $34,000
Q2 2021 Jul 21, 2021	SELL	$1.67 - $3.98 $1,670 - $3,980	-1,000 Reduced 2.53%	38,500 $65,000
Q1 2021 Apr 29, 2021	SELL	$2.12 - $7.15 $34,450 - $116,187	-16,250 Reduced 29.15%	39,500 $106,000
Q4 2020 Jan 26, 2021	BUY	$2.02 - $6.0 $112,615 - $334,500	55,750 New	55,750 $300,000

263K

Ticker CYDY
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 813,040,000
Market Cap $179M
Description
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as c...

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

Stay updated on Hollencrest Capital Management with notifications on news.